GeoVax Labs Inc (GOVX)

[Tonyeight]

NEWS OUT =NEWS OUT =========NEWS OUT ==READ FELLAS
GeoVax Presenting at Upcoming October European Scientific Conferences
GeoVax Presenting at Upcoming October European Scientific Conferences
GlobeNewswire•October 15, 2019
Unique Platform Continues to be Recognized for Distinct Benefits

ATLANTA, GA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company specializing in developing human vaccines, announced today that it will be represented during presentations at the following upcoming European scientific conferences.

Festival of Biologics / World Immunotherapy Congress, Basel, Switzerland, Oct. 15-17

Farshad Guirakhoo, PhD, GeoVax Chief Scientific Officer, will deliver an oral presentation entitled, Utilizing a Live Modified Vaccinia Ankara Virus to Deliver Cancer Antigens in Highly Immunogenic Forms of Virus Like Particles. In this talk, Dr. Guirakhoo will illustrate advantages of the inherently safe MVA-VLP platform to deliver “cancer like MUC1” antigens designed to break the host tolerance against MUC1 and train the body’s own immune system to attack and kill cancer cells.

International Society for Virology (ISV), 2019 Annual Congress, Ghent, Belgium, Oct. 27-29

During this conference, Dr. Guirakhoo will deliver an oral presentation entitled, Development of Single Dose Vaccines against Emerging and Reemerging Infectious Diseases Using a Novel MVA-VLP Vector. In this talk, latest data for Ebola, Marburg, Lassa and Zika vaccines, pathogens selected from three different families of viruses, will demonstrate broad utility of GeoVax’s vector platform for developing safe and effective single-dose vaccines for many known emerging and re-emerging infectious diseases.

World Vaccine Congress-Europe, Barcelona, Spain, Oct. 29-31

During this conference, Dr. Guirakhoo will deliver an oral presentation entitled, MVA-VLP as a safe and effective platform for delivery of multi-antigen vaccine candidates for infectious diseases and cancer. In this talk, the most relevant vaccine safety and efficacy data, including characterization of humoral and T cell responses, for selected viral infectious disease targets will be presented as examples for a broad utility of the platform for other indications such as malaria, HPV, HBV and cancer immunotherapy.

Commenting on these presentations, David Dodd, GeoVax CEO, stated, “We are pleased in the continued and increasing recognition of the GeoVax MVA-VLP technology and expertise, ranging from immuno-oncology to various infectious diseases. Such invited presentations provide us the opportunity to further underscore the potential value of our developments focused on improving the lives of millions worldwide, while also progressing our collaboration discussions with both public and private organizations.”

/bhttps://finance.yahoo.com/news/geovax-presenting-upcoming-october-european-130000356.html